Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$57.00

7.81 (15.88%)

06:20
11/26/19
11/26
06:20
11/26/19
06:20

Arrowhead price target raised to $72 from $54 at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $72 from $54 and reiterates an Overweight rating on the shares following last night's results. The company expects to have three pivotal Phase III trials underway in 2020, Tenthoff tells investors in a research note. He believes Arrowhead's RNAi will address both orphan and broader cardiovascular indications characterized by high triglycerides.

ARWR Arrowhead
$57.00

7.81 (15.88%)

11/19/19
CANT
11/19/19
NO CHANGE
Target $50
CANT
Overweight
Arrowhead price target raised to $50 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Arrowhead Pharmaceuticals to $50 from $24 and maintains a Neutral rating on the shares. The stock is up 35% since its R&D day on October 18 and up 287% year-to-date, Young tells investors in a research note. She thinks RNAi is a "growing, differentiated" modality and Arrowhead's TriM RNAi platform is a "significant step forward" versus prior technology. Young, however, finds the shares are fairly valued here and would wait for a better entry point.
11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform from Neutral at Baird
Baird analyst Madhu Kumar upgraded Arrowhead to Outperform from Neutral with a $70 price target.
11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform after Medicines Company takeover at Baird
As previously reported, Baird analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals (ARWR) to Outperform from Neutral with a price target of $70, up from $39, after Medicines Company (MDCO) announced a definitive agreement to be acquired by Novartis (NVS). That deal forces Kumar to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease, the analyst tells investors. Given the early positive efficacy for Arrowhead's ANGPTL3 and APOC3 RNAi drugs presented at the American Heart Association meeting, Kumar believes these programs have "the chance to dominate the ANGPTL3 and APOC3 landscapes," though cautions both are "quite early."
11/25/19
11/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deckers Brands (DECK) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying the stock's upside guidance potential amid improving weather outlook for the 2nd half of FY20 and also cites the company's "compelling" portfolio structure along with its "cash cow" UGG brand. 2. Wendy's (WEN) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying he left recent management meetings with greater confidence in the company's sales and EBITDA drivers over the next few years, especially the breakfast launch planned for 2020. 3. Hasbro (HAS) upgraded to Buy from Neutral at UBS with analyst Arpine Kocharyan saying expectations for the company have seen a "meaningful reset" after a weak Q3 results, but he sees upside in the stock thanks to the better than expected revenue and the cost synergies from Entertainment One acquisition, along with the momentum of its gaming portfolio. 4. Nvidia (NVDA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Joseph Moore saying both of Nvidia's gaming and data center segments fell short of expectations over the course of 2019, but investments made this year in the gaming business should pay off in 2020 while recent Cloud commentary indicates that the inflection in "conversational AI" is real and new Nvidia products should ease concerns about competition in the data center segment. 5. Arrowhead (ARWR) upgraded to Outperform from Neutral at Baird with analyst Madhu Kumar saying Medicines Company's (MDCO) announcement of a definitive agreement to be acquired by Novartis (NVS) forces him to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

10:25
12/09/19
12/09
10:25
12/09/19
10:25
General news
Concerns over a year-end spike in the money markets »

Concerns over a year-end…

10:25
12/09/19
12/09
10:25
12/09/19
10:25
Conference/Events
JPMorgan Mexican strategist to hold an analyst/industry conference call »

Mexican Equity Strategist…

10:25
12/09/19
12/09
10:25
12/09/19
10:25
Conference/Events
UBS alternative energy windham to hold an analyst/industry conference call »

Alternative Energy &…

ZG

Zillow

$40.54

-0.18 (-0.44%)

, SPCE

Virgin Galactic

$8.20

0.92 (12.64%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ZG

Zillow

$40.54

-0.18 (-0.44%)

SPCE

Virgin Galactic

$8.20

0.92 (12.64%)

PAA

Plains All American

$17.29

-0.01 (-0.06%)

PAGP

Plains GP Holdings

$17.37

0.01 (0.06%)

SSKN

Strata Skin Sciences

$2.20

0.04 (1.85%)

ZYME

Zymeworks

$41.25

-0.45 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 30

    Dec

  • 04

    Feb

MMM

3M

$169.82

-1.675 (-0.98%)

, PNC

PNC Financial

$153.68

-0.13 (-0.08%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MMM

3M

$169.82

-1.675 (-0.98%)

PNC

PNC Financial

$153.68

-0.13 (-0.08%)

M

Macy's

$14.96

-0.19 (-1.25%)

CVX

Chevron

$117.18

-0.8 (-0.68%)

HBIO

Harvard Bioscience

$2.83

-0.12 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 15

    Jan

QRVO

Qorvo

$109.72

3.04 (2.85%)

, SWKS

Skyworks

$104.55

3.15 (3.11%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

QRVO

Qorvo

$109.72

3.04 (2.85%)

SWKS

Skyworks

$104.55

3.15 (3.11%)

FATE

Fate Therapeutics

$19.69

6.05 (44.35%)

WING

Wingstop

$84.26

4.04 (5.04%)

HUN

Huntsman

$23.31

0.48 (2.10%)

FTV

Fortive

$74.68

1.82 (2.50%)

DOW

Dow Inc.

$53.29

0.04 (0.08%)

KRA

Kraton

$23.96

0.92 (3.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

TPR

Tapestry

$25.85

0.305 (1.19%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Options
Upside February calls see heavy trading in Tapestry »

Upside February calls see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTX

SpringsWorks Therapeutics

$28.00

3.01 (12.04%)

, GSK

GlaxoSmithKline

$45.64

0.13 (0.29%)

10:19
12/09/19
12/09
10:19
12/09/19
10:19
Hot Stocks
SpringsWorks reports Glaxo presentation of preclinical data on nirogacestat »

SpringWorks Therapeutics…

SWTX

SpringsWorks Therapeutics

$28.00

3.01 (12.04%)

GSK

GlaxoSmithKline

$45.64

0.13 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/09/19
12/09
10:17
12/09/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$44.49

3.56 (8.70%)

10:16
12/09/19
12/09
10:16
12/09/19
10:16
Hot Stocks
Agios Pharmaceuticals reports new data from DRIVE PK Phase 2 study »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/09/19
12/09
10:16
12/09/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$22.25

7.85 (54.51%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Hot Stocks
Forty Seven announces preclinical proof-of-concept data for FSI-174 »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

NKTR

Nektar

$22.00

1.55 (7.58%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Hot Stocks
Nektar announces presentation of data for NKTR-255 at ASH »

Nektar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

UPS

UPS

$116.87

-0.67 (-0.57%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Hot Stocks
UPS reports expansion of UPS Worldwide Express, Express Plus across 40 countries »

UPS announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$60.30

-0.69 (-1.13%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Options
Centene put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CNST

Constellation Pharmaceuticals

$47.50

3.4 (7.71%)

10:14
12/09/19
12/09
10:14
12/09/19
10:14
Hot Stocks
Breaking Hot Stocks news story on Constellation Pharmaceuticals »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ACHN

Achillion

$6.19

0.02 (0.32%)

10:14
12/09/19
12/09
10:14
12/09/19
10:14
Hot Stocks
Achillion reports 'positive' data from Phase 2 danicopan, eculizumab study »

Achillion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ATRA

Atara Biotherapeutics

$14.24

0.25 (1.79%)

10:12
12/09/19
12/09
10:12
12/09/19
10:12
Hot Stocks
Atara reports updated long-term clinical results from Tab-cel EBV+ PTLD study »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$102.78

-0.525 (-0.51%)

10:12
12/09/19
12/09
10:12
12/09/19
10:12
Conference/Events
Globant management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 16

    Jan

CNST

Constellation Pharmaceuticals

$47.50

3.4 (7.71%)

10:12
12/09/19
12/09
10:12
12/09/19
10:12
Hot Stocks
Constellation Pharmaceuticals provides update on MANIFEST clinical trial »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

DTIL

Precision BioSciences

$18.00

-1.66 (-8.44%)

10:11
12/09/19
12/09
10:11
12/09/19
10:11
Hot Stocks
Breaking Hot Stocks news story on Precision BioSciences »

Precision BioSciences Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

MTEM

Molecular Templates

$12.23

(0.00%)

10:10
12/09/19
12/09
10:10
12/09/19
10:10
Hot Stocks
Molecular Templates announces presentations of two posters at ASH »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$31.72

0.545 (1.75%)

10:10
12/09/19
12/09
10:10
12/09/19
10:10
Conference/Events
Avis Budget management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

XNCR

Xencor

$41.27

0.25 (0.61%)

10:08
12/09/19
12/09
10:08
12/09/19
10:08
Hot Stocks
Xencor presents Initial Data from Phase 1 Study of XmAb 13676 »

Xencor announced initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

SGEN

Seattle Genetics

$117.12

-0.4 (-0.34%)

, TAK

Takeda Pharmaceutical

$20.12

-0.15 (-0.74%)

10:08
12/09/19
12/09
10:08
12/09/19
10:08
Hot Stocks
Seattle Genetics, Takeda announce additional analyses of Adcetris »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$117.12

-0.4 (-0.34%)

TAK

Takeda Pharmaceutical

$20.12

-0.15 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.